Navigation Links
Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
Date:1/4/2008

ASHBURN, Va., Jan. 4 /PRNewswire/ -- Innocoll, Inc., a privately-held specialty pharmaceutical company, announced that the first of a series of planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the management of post-operative pain, has commenced dosing.

Innocoll's BUPIVACAINE SURGICAL IMPLANT is a biodegradable and fully bioresorbable matrix of purified fibrillar collagen impregnated with the local anesthetic, bupivacaine, which has been specifically developed and formulated using Innocoll's proprietary CollaRx sponge technology. It is under development in the US and Europe for the management of post-operative pain following moderate/major abdominal, gynecological, abdominal, thoracic, and orthopedic surgeries.

Post-operative pain is typically controlled with narcotic analgesics such as morphine, but systemic administration of these drugs can result in unfavorable side effects including suppression of breathing, sedation, nausea and vomiting, and can also affect patient recovery. Innocoll's BUPIVACAINE SURGICAL IMPLANT is intended to provide pain control directly at the surgical site and thus reduce the level of additional analgesia required following surgery. The collagen matrix naturally biodegrades over a few days and the bupivacaine is released to provide local analgesia for up to 96 hours post- operatively. A key feature of Innocoll's product is the ability to implant it directly into the surgical cavity and at different layers within the wound, such as across the peritoneum incision and directly below the skin incision, which enables localized treatment of both the incisional and deep, visceral pain components normally associated with moderate and major surgery. The bioresorbable nature of the collagen matrix also offers significant clinical benefits and convenience advantages over ambulatory infusion pumps often used to provide c
'/>"/>

SOURCE Innocoll Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
3. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  TechAtlas Group ... for their competitive landscape map for the Chronic ... over 90 international companies with drugs and devices ... CKD and its sequelae. (Logo:  ... , hypertension - renal denervation ...
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- The ... recombinant proteins, is placing renewed emphasis on alternate ... rise as a number of factors are converging ... pharmaceutical makers and their delivery device partners . ... refractory conditions, the growing trend toward self-administration for ...
(Date:5/17/2013)... LAKES, Fla. , May 17, 2013 Fuse ... and delivery technology company that is developing new, patent-pending technologies ... minerals, announced today that it will hold a business update ... Wednesday, May 22 nd , 2013 at 4:30 PM ET. ... Tuffin will host the call and will be ...
Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2
(Date:5/17/2013)... May 17 (HealthDay News) -- There are apps that turn ... a GPS system, and now there,s an app that may ... attack. The app, which was designed by engineers and ... severe heart attacks, called STEMIs, before patients get to the ... but it has undergone field testing. In a STEMI ...
(Date:5/17/2013)... a higher burden of disease and lower life expectancy ... of men are notably absent from the strategies of ... this week,s Lancet . , The article reinterprets ... which shows that all of the top ten causes ... risk factors driving rates of ill-health around the world, ...
(Date:5/17/2013)... Florida Hospital Tampa is ... and implement programs providing education, support and development to ... special emphasis on health-related initiatives and those events which ... partnership started in January of 2012 with the formal ... until March 19, 2015. The cooperative educational program entitled, ...
(Date:5/17/2013)... 17 (HealthDay News) -- Teen bullies are more likely ... finds. UT Dallas researchers analyzed several decades of ... All of them had similar working-class backgrounds and most ... were in their mid-50s. Nearly half of the ... years engaged in some form of criminal activity -- ...
(Date:5/17/2013)... transplants to treat a common type of liver cancer ... according to new research. The Italian study, published ... found that the AIDS-causing virus doesn,t affect survival rates ... this particular type of liver cancer, called hepatocellular carcinoma ... more aggressive in people with HIV and it is ...
Breaking Medicine News(10 mins):Health News:Heart Attack? Doctors Soon May Have an App for That 2Health News:Heart Attack? Doctors Soon May Have an App for That 3Health News:Global health policy fails to address burden of disease on men 2Health News:Florida Hospital Tampa Partners with Hillsborough County Public Schools Offering Health Educational Programs and Support to Students 2Health News:Florida Hospital Tampa Partners with Hillsborough County Public Schools Offering Health Educational Programs and Support to Students 3Health News:HIV No Barrier to Getting Liver Transplant, Study Finds 2
... twice before buying their next pair of high-heels or pumps, ... Hebrew SeniorLife in a new study of older adults and ... women wear, specifically high-heels, pumps and sandals, may cause future ... who reported hind-foot pain regularly wore these types of shoes ...
... individuals from the field of pharmaceutical research are expected to ... - 12, 2009 at the Los Angeles Convention Center in ... have the opportunity to present new research, methods and technologies ... only is the meeting the premiere international event for the ...
... ... healthcare professionals, today announced that it has acquired the assets of Medical Concepts Staffing ... , ... (PRWEB) September 28, 2009 -- Temps Inc., ( www.tempsinc.net ) a national provider of ...
... cons of cancer screen not understood, research shows, , MONDAY, ... told the pros and cons of PSA tests, two new ... they can,t predict which cancers are aggressive and which are ... leads to overtreatment, which can have immediate consequences, such as ...
... cells to ignore premature signals to stop producing important proteins. ... Journal of Experimental Medicine , the findings could lead to ... dystrophy, that are sparked by missing proteins. "When DNA ... than the end of a protein-producing signal, they act like ...
... of Common Human Disease has been chosen as one ... of Health (NIH) grant for Centers of Excellence to ... million over five years. "We,re grateful for ... how epigenetic control affects disease," says the center,s director, ...
Cached Medicine News:Health News:Institute for Aging Research study links high-heels to heel and ankle pain 2Health News:Temps Inc. Acquires Medical Concepts Staffing Business From Analysts International Corporation 2Health News:Men Not Being Told Enough About PSA Tests 2Health News:Men Not Being Told Enough About PSA Tests 3Health News:Men Not Being Told Enough About PSA Tests 4Health News:UCLA study identifies 2 chemicals that could lead to new drugs for genetic disorders 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: